Find a clinical trial

Researchers all over Australia and New Zealand are running clinical trials for people at different ages and stages of type 1 diabetes. Use our clinical trial finder below to find clinical trials near you.

Tailor your results by using the filters below

Tirzepatide in type 1 diabetes: cardiometabolic effects (TIRTLE)

Cardiovascular disease and its risk factors are prominent issues in type 1 diabetes. There is a need to identify treatments that can address weight, blood sugar management and heart disease risk factors in type 1 diabetes. Tirzepatide is a medication usually used in type 2 diabetes. Whether tirzepatide improves health in type 1 diabetes has not been studied before. The TIRTLE study is a clinical trial studying the effect of tirzepatide on weight and metabolism in adults with type 1 diabetes.

Treatment

The study medication in this trial is given by injection into the skin once a week for 12 weeks. For every 2 participants, 1 will receive the study medication, and 1 will receive placebo. The allocation of medication is done randomly.

Study visits

Volunteers briefly visit the Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, every week to receive their treatment dose. There are also:

– 2 visits before treatment: visit 1 – 1.5 hours with option for online attendance, visit 2 – up to 3 hours at the Garvan Institute

– 2 visits at the end of treatment, after 12 weeks: visit 3 – 1.5 hours with option for online attendance, visit 4 – up to 3 hours at the Garvan Institute

– In between, volunteers briefly visit the Garvan Institute every week to receive their treatment dose.

Benefits of participation

In addition to improving knowledge about weight management and metabolic health in type 1 diabetes, test results such as body composition measurements will be shared with you.

There is no cost to participate in the study.

Contact

Email: TIRTLE@garvan.org.au

Phone : 0491 731 769

KEY REQUIREMENTS

Location

Age 18-60 years

2 years since T1D diagnosis

BMI greater than or equal to 30kg/m2

The legal context of collecting, storing and using electronic data obtained from active implanted medical devices used for diabetes in Australia: The consumer experience

There are now many health devices that can be implanted into consumers’ bodies to help with the monitoring their health condition. These devices can communicate health data back to data storage devices where clinicians can review and act accordingly to help maintain consumers’ health. Such advances have raised questions about privacy and consent for the use of consumers health data.

We would like to talk to people who have consented to an implanted active medical device for the management of their diabetes, or have consented to such a device on behalf of another person. The types of implants we are interested in are those that are medically implanted into the user and rely on wireless or Bluetooth connectivity to communicate patient information, such as blood glucose monitors (either connected to an insulin pump or not) that transmit information or data from the implant to an external source (such as the clinical team, the manufacturer or an external app on your phone or computer).

We want to talk with people about their experiences in providing consent to explore whether the existing laws about this topic are sufficient in ensuring informed consent for the collection, storage and future use of the data that is sent and received from those devices.

Key requirements: If you have provided consent for the implantation of an active medical device for the management of your diabetes or consent on behalf of another, we would like to talk with you.

Location: Interviews will be undertaken using Microsoft Teams, so participants can be located anywhere in Australia.

Age: Over 18

Website link: For more information about the study, please contact the student researcher, Rebecca Millar, via email at rmillar@swin.edu.au.

KEY REQUIREMENTS

Location Any location (virtual)

Age

T1D RELAY – Rituximab-pvvr and Abatacept Newly Diagnosed Study

The medicines Rituximab-pvvr and abatacept have both been shown to protect insulin-producing beta cells from immune attack, allowing people with newly diagnosed type 1 diabetes (T1D) to continue producing their own insulin for longer. This trial will look at whether combining these two medicines is better at protecting beta cells from immune attack than rituximab-pvvr alone.

Who can get involved

• Aged between 8 and 45 years.
• Evidence of insulin production, determined by one or more diabetes-related antibodies and detectable C-peptide during a mixed-meal tolerance test (MMTT).
• Up to date with immunisation schedule, including COVID-19 and flu boosters.

Treatment

Participants in this study will receive weekly rituximab-pvvr by intravenous infusion (into a vein in the arm) for four weeks. Participants will then receive weekly injections of abatacept OR placebo (inactive equivalent). Two in every three participants will receive active treatment (abatacept), while one in three will receive placebo. The allocation of medication will be done randomly.

Study visits

Participants will be required to attend 16 visits at a participating clinical centre over a two-year treatment period and a further five visits over a two year follow up period after the treatment. The first four visits for the rituximab-pvvr infusion will take up to eight hours. The remaining visits will vary in duration from one to four hours.

Benefits of participation

All participants in this study will receive active treatment in the form of rituximab-pvvr. Two in every three participants will then receive a second active treatment called abatacept. In addition to the potential for these study medications to delay the progression of T1D, participants will be closely monitored and blood glucose levels managed intensively. This may reduce the risk of long-term complications of T1D, as well as helping remaining beta cells in the pancreas to continue making insulin on their own.

This trial is being undertaken by the JDRF-funded Australasian Type 1 Diabetes Immunotherapy Collaborative (ATIC).

To find out if you are eligible or if you have any questions contact the ATIC team.

Learn More

KEY REQUIREMENTS

Location Melbourne

Age 8-45 years

Within three months of diagnosis with T1D

STOP-T1D – ATG Prevention Study

Antithymocyte globulin (ATG) is commonly used to prevent transplant rejection. Early research showed that ATG improved blood glucose management and preserved pancreas function in people with recently diagnosed type 1 diabetes (T1D). The STOP-T1D trial will test if ATG can delay or prevent people moving from the from pre-symptomatic stage (Stage 2) to clinically diagnosed T1D (Stage 3).

Stage 2 T1D is when people have two or more autoantibodies and abnormal blood glucose levels. This indicates the immune system has already started attacking the body’s insulin-producing beta cells in the pancreas. These autoantibodies and abnormal blood glucose levels can be detected in a blood test by a health professional. The presence of these autoantibodies increases the risk of progressing to Stage 3 T1D, which is when clinical diagnosis of T1D occurs.

Read more about the 3 stages of T1D development.

Who can get involved

• Aged between 12 and 35 years.
• Be at high risk of progressing to Stage 3 T1D, determined by a positive screening blood test for antibodies and slightly elevated blood glucose.
• Up to date with immunisation schedule, including COVID-19 and flu boosters.
• Other markers indicative of high risk of progression to Stage 3 T1D.

Treatment

The study medication in this trial is given by intravenous infusion (through a vein in the arm) on two consecutive days. For every three participants, two will receive ATG and one will receive placebo. The allocation of medication will be done randomly.

Study visits

The two treatment visits will take six to 10 hours for the infusion and a further two hours for monitoring (8-12 hours in total). Participants will visit the trial site two weeks after the second treatment, then every three to six months for one year. Participants will continue to visit the trial site for monitoring twice a year for up to four years following treatment.

Benefits of participation

In addition to potentially delaying or preventing progression of T1D, benefits to participating in the study include close monitoring and follow up by the research team. If you progress to Stage 3 T1D, the study blood tests will likely show this before any symptoms appear. Early diagnosis and commencement of insulin treatment largely eliminates the risk of a serious condition called diabetic ketoacidosis (DKA).

This trial is being undertaken by the JDRF-funded Australasian Type 1 Diabetes Immunotherapy Collaborative (ATIC).

To find out if you are eligible or if you have any questions contact the ATIC team.

Learn More

KEY REQUIREMENTS

Location Melbourne

Age 12-35 years

Stage 2 T1D: Two or more diabetes related antibodies and elevated blood glucose levels. High risk of progression to Stage 3 T1D (clinically diagnosed T1D)

Type1Screen: Screening for early-stage type 1 diabetes in family members

JDRF Australia funds a program where family members of those with type 1 diabetes (T1D) can be screened for the early stages of the condition. Identifying if someone is in the early stages of T1D can bring about long-term health benefits. 

We previously thought that T1D starts shortly before (or when) people show the 4T symptoms: thirst, toilet (frequent urination), thinness and tiredness. But decades of research have discovered that there are several detectable changes in people before these symptoms develop. These changes can occur months or even years before diagnosis typically occurs. People in these stages have ‘early-stage’ or ‘pre-symptomatic’ T1D and can be easily identified with a blood test. Read more about the stages of T1D here 

JDRF funds Type1Screen which provides free screening to family members of those diagnosed with T1D to test whether they are in the early stages of the condition. Screening family members is important as they are at increased risk of developing T1D when compared to the general population. 

The Type1Screen program has already screened over 1,000 people and is looking for more family members who may benefit.  

What’s involved in screening for T1D?  

A young boy is looking at the camera with a band aid on his thumb. On the table below him sits a card with blood drops

Carter, doing his own Type1Screen… it’s that easy

Detecting the early stages of T1D involves a simple blood test. This can be done at home using a fingerpick test where five drops of blood are put on a card. The card is sent to a lab in Melbourne where the blood is analysed for the presence of islet autoantibodies. These are markers of early-stage T1D. Read more about autoantibodies here 

If the test is positive for autoantibodies, a venous blood test (needle in the arm) is required to confirm the findings. If confirmed, you will be put in contact with the closest participating diabetes centre for education and follow-up. You will also be offered opportunities to participate in clinical trials that aim to prevent or delay the onset of Stage 3 T1D. Current T1D clinical trials and studies recruiting in Australia can be found on our clinical trial page. 

Benefits of screening 

Screening for early-stage T1D has many benefits to both the person and their family. These include: 

  1. Reducing the trauma of diagnosis: By picking up T1D early, we can better support families so that the transition to treatment is less sudden and stressful 
  2. Reducing diabetic ketoacidosis at diagnosis: detection of early-stage T1D, combined with monitoring and education, can significantly reduce the rate of developing a dangerous condition called diabetic ketoacidosis (DKA). Left untreated, DKA can be fatal. DKA at diagnosis of T1D is also linked with worse long-term health effects, so preventing it from happening is important. 
  3. Opportunities to test therapies to delay or prevent the condition: Identifying people in early-stage T1D enables them the opportunity to participate in trials testing therapies to slow down the progression of T1D. In future, when these therapies become available, screening for early-stage T1D will allow us to offer them to those who will most benefit from the treatment. 

Nicole and her daughters Alyssia and Chelsea who have participated in Type1Screen

On a mission to help my partner Mathew (diagnosed at 26) better manage his own Type 1 diabetes, I stumbled across Type1Screen.  I didn’t hesitate to quickly register our daughters Alyssia (10) & Chelsea (5).  I had my suspicions about Alyssia, so when we received a phone call from the Type1Screen team I wasn’t surprised. She had tested positive for the antibodies.  On the 16th of March bloods were taken and a glucose test was done to confirm her levels. On the 18th of March she was clinically diagnosed with Type 1 Diabetes at the Royal Children’s Hospital. As upsetting as it was to find out Alyssia had Type 1 like her dad, we are extremely happy it happened the way it did. Thanks to Type1Screen Alyssia presented to the hospital as a healthy happy kid when most start off in ICU, so for that we are honoured to have found Type1Screen. Moving forward I have arranged for Chelsea to be screened every 6 months.Nicole, Mum to Alyssia (10) and Chelsea (5) 

Am I eligible?  

People who are eligible for screening under Type1Screen must be:  

  • Aged over 2 years 
  • Live in Australia  
  • Have a relative diagnosed with T1D or have previously tested positive for an islet antibody test 

Where can I find more information?  

You can find more information on the Type1Screen website, Facebook, Instagram or by contacting the Type1Screen team via: (03) 9342 7063 or Type1Screen@mh.org.au 

More information can also be found on the Type1Screen FAQs.  

JDRF’s role in supporting screening for T1D 

JDRF is committed to a world without T1D. That’s why we fund research projects which will ultimately prevent people from reaching clinical T1D (Stage 3 T1D). We fund two screening projects under the JDRF Type 1 Diabetes Clinical Research Network (CRN): Type1Screen and the Type 1 Diabetes National Screening Pilot. Type1Screen has been supported by the CRN since 2019. 

Learn More

KEY REQUIREMENTS

Location ACT, NSW, NT, QLD, SA, TAS, VIC, WA

Age Minimum 2 years

Have a relative diagnosed with T1D or have previously had a positive antibody test

Fenofibrate and microvascular events in type 1 diabetic retinopathy (FAME-1-EYE) study

This clinical trial is investigating whether fenofibrate, a drug used to lower cholesterol, can slow or reverse eye damage in adults with type 1 diabetes. Fenofibrate has been shown to slow eye damage in type 2 diabetes, and researchers are now investigating whether the same effect will be seen in T1D.

This study has been approved by the Northern Sydney Local Health District Human Research Ethics Committee.

ANZCTR listing: ACTRN12611000249954

Learn More

KEY REQUIREMENTS

Location NSW, QLD, SA, VIC, WA, New Zealand, Hong Kong

Age 18+ years

Non-proliferative diabetic retinopathy (NPDR)

ETDRS score 35-53

Making friends with yourself: Self-compassion for young people with type 1 diabetes

Our researchers are recruiting young Australians between the ages of 14 and 17, who are diagnosed with Type 1 Diabetes and who are using continuous glucose monitoring. The course consists of 8 x 1.5-hour group sessions.  The first session is scheduled for Wednesday 30th March 2022. Sessions will be delivered via Zoom and take place from 4-5:30pm AWST. 

For more information contact Karina Prentice

karina.prentice@telethonkids.org.au

KEY REQUIREMENTS

Location WA

Age 14-17 years

Using continuous glucose monitoring (CGM)

Cord reinfusion in diabetes (CORD) pilot study

Cell Care is partnering with The Children’s Hospital at Westmead, New South Wales, in a world–first study investigating the potential of cord blood to prevent or delay the onset of type 1 diabetes in children at high risk of developing the disease.

The CORD study has been approved by the Sydney Children’s Hospitals Network Human Research Ethics Committee.

ANZCTR listing: ACTRN12613000186752

Learn More

KEY REQUIREMENTS

Location NSW

Age 1-15 years

First- or second-degree relative with T1D

Children with stored cord blood, or parents expecting a child and planning cord blood storage

Become a Game Changer

Get the latest research updates straight to your inbox and be the first to hear about new clinical trials.

Researchers: is your T1D clinical trial not displayed here?

Submit a trial